Q3 2017 EPS Estimates for Supernus Pharmaceuticals, Inc. Increased by Analyst (SUPN)
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Equities researchers at Jefferies Group increased their Q3 2017 earnings estimates for Supernus Pharmaceuticals in a research report issued to clients and investors on Monday. Jefferies Group analyst D. Steinberg now expects that the specialty pharmaceutical company will post earnings per share of $0.27 for the quarter, up from their previous estimate of $0.24. Jefferies Group currently has a “Buy” rating and a $51.00 target price on the stock. Jefferies Group also issued estimates for Supernus Pharmaceuticals’ FY2017 earnings at $1.01 EPS and FY2018 earnings at $1.61 EPS.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The company had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/q3-2017-eps-estimates-for-supernus-pharmaceuticals-inc-increased-by-analyst-supn.html.
A number of other research firms have also commented on SUPN. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Thursday, July 13th. Piper Jaffray Companies lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 price objective for the company. in a research note on Monday, July 17th. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Janney Montgomery Scott assumed coverage on shares of Supernus Pharmaceuticals in a research note on Friday, July 14th. They issued a “neutral” rating and a $47.00 price objective for the company. Finally, Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, July 5th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $48.43.
Supernus Pharmaceuticals (SUPN) opened at 42.10 on Tuesday. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $44.95. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of 21.25 and a beta of 1.31. The firm’s 50 day moving average price is $42.27 and its 200-day moving average price is $33.33.
In related news, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction on Friday, May 26th. The shares were sold at an average price of $35.90, for a total value of $89,750.00. Following the transaction, the vice president now owns 37,500 shares in the company, valued at approximately $1,346,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 10,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $39.86, for a total transaction of $398,600.00. Following the completion of the transaction, the vice president now owns 27,500 shares in the company, valued at approximately $1,096,150. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,291 shares of company stock valued at $962,766. 6.70% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. increased its position in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares during the period. Victory Capital Management Inc. increased its position in Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in Supernus Pharmaceuticals during the first quarter valued at about $127,000. Intrust Bank NA bought a new position in Supernus Pharmaceuticals during the second quarter valued at about $218,000. Finally, Fortaleza Asset Management Inc. bought a new position in Supernus Pharmaceuticals during the first quarter valued at about $160,000. Hedge funds and other institutional investors own 94.39% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.